Pvsripo (Chimeric Poliovirus (Pv), Consisting Of The Type-1 Sabin Vaccine Strain Carrying A Foreign Internal Ribosome Entry Site (Ires) From Human Rhinovirus Type-2) (Hrv2)
Glioblastoma
Explore 342 assets in Glioblastoma →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Darell Bigner
Modality
other_biological
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06177964CT.gov Lerapolturev (PVSRIPO) in GBM | — | Recruiting | — | — | — |
NCT04479241CT.gov LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma | — | Completed | — | — | — |
NCT03043391CT.gov Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | — | Completed | — | — | — |
NCT01491893CT.gov PVSRIPO for Recurrent Glioblastoma (GBM) | — | Completed | — | — | — |
NCT04599647CT.gov EAP for the Treatment of Glioblastoma With PVSRIPO | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pvsripo (Chimeric Poliovirus (Pv), Consisting Of The Type-1 Sabin Vaccine Strain Carrying A Foreign Internal Ribosome Entry Site (Ires) From Human Rhinovirus Type-2) (Hrv2) (this asset) | Darell Bigner | P2 | CCC · 50 |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Capecitabine | Northwell Health | P2 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Carboplatin | Sichuan Honghe Biotechnology Co., Ltd. | P3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Pvsripo (Chimeric Poliovirus (Pv), Consisting Of The Type-1 Sabin Vaccine Strain Carrying A Foreign Internal Ribosome Entry Site (Ires) From Human Rhinovirus Type-2) (Hrv2)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Glioma | — | P2 | B · 58 |
| Brain Neoplasm | — | P2 | CCC · 52 |
| Melanoma | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pvsripo (Chimeric Poliovirus (Pv), Consisting Of The Type-1 Sabin Vaccine Strain Carrying A Foreign Internal Ribosome Entry Site (Ires) From Human Rhinovirus Type-2) (Hrv2) in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pvsripo-chimeric-poliovirus-pv-consisting-of-the-type-1-sabin-vaccine-strain-carrying-a-foreign-internal-ribosome-entry-site-ires-from-human-rhinovirus-type-2-hrv2-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →